Results 371 to 380 of about 263,255 (408)

Antisense Anticancer Oligonucleotide Therapeutics

Current Cancer Drug Targets, 2001
Recent progress made in molecular biology, biotechnology, and genetics, especially in identifying, cloning, sequencing and characterization of normal and pathogenic genes, has led to the development of genetic therapy. Major efforts in the field can be summarized in two general approaches: gene therapy and antisense therapy. The second is to deliver to
Gautam Prasad, Hui Wang, Ruiwen Zhang, John K. Buolamwini   +3 more
openaire   +3 more sources

Antisense Oligonucleotide-Conjugated Nanostructure-Targeting lncRNA MALAT1 Inhibits Cancer Metastasis.

ACS Applied Materials and Interfaces, 2018
Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), a long noncoding RNA (lncRNA) located in the cell nucleus, is a critical regulator of tumor cell migration. Antisense oligonucleotides (ASOs), which can downregulate the expression level of
N. Gong, Xucong Teng, Jinghong Li, Xing-jie Liang   +3 more
semanticscholar   +1 more source

Antisense Oligonucleotides

2006
Publisher Summary Antisense oligonucleotides (ASO) offer significant advantages over traditional methods in terms of specificity and versatility. ASOs validate the function of genes in vitro and in vivo. In addition, antisense oligonucleotides are developed as drugs with many products currently being tested in clinical trials. ASOs are short stretches
Erich Koller, Nicholas M. Dean
openaire   +2 more sources

Antisense oligonucleotides in cutaneous therapy

Pharmacology & Therapeutics, 2001
Antisense oligonucleotides have been the subject of intense interest as research tools to elucidate the functions of gene products and as therapeutic agents. Initially, their mode of action was poorly understood and the biological effects of oligonucleotides were often misinterpreted.
Paul J. White, Christopher J. Wraight
openaire   +3 more sources

History of Antisense Oligonucleotides

2003
Biological science is a rapidly flowing experimental stream, at times encountering a dam that impedes further progress. At such a pomt, a single crack may induce a major breakthrough Discovery of the double helical structure of DNA in 1953 (1) caused such an event, with flooding of new information into the area now known as molecular biology.
openaire   +3 more sources

Antisense Oligonucleotides: Promise and Reality

Annual Review of Pharmacology and Toxicology, 2001
Antisense oligonucleotides have been used for more than a decade to downregulate gene expression. Phosphodiester oligonucleotides are nuclease sensitive, and the more nuclease-resistant phosphorothioate oligonucleotides are now in common use in the laboratory and have entered clinical trials.
Cy A. Stein, Irina V. Lebedeva
openaire   +3 more sources

Mini-antisense Oligonucleotides

Nucleosides and Nucleotides, 1997
Abstract A new strategy of selective DNA target modification was proposed. The using of reactive derivatives of short oligonucleotides in the presence of flanking effector pair allows one to modify DNA target only when the perfect complementary complex of DNA target and oligonucleotide tandem is formed.
Dmitrii V. Pyshnyi, Valentina F. Zarytova, Lokhov Sg, Inna A. Pyshnaya, E. M. Ivanova   +4 more
openaire   +2 more sources

Antisense Oligonucleotide Therapy in Urology

Journal of Urology, 2002
Antisense oligonucleotides are short modified DNA or RNA molecules designed to bind selectively messenger RNA and inhibit synthesis of the encoded protein. In the last 20 years antisense technology has emerged as an exciting and promising strategy, especially for treating cancer.
Ingo Kausch, A. Böhle
openaire   +3 more sources

Progress in Antisense Oligonucleotide Therapeutics

Annual Review of Pharmacology and Toxicology, 1996
The past several years have seen substantial progress in the development of antisense oligonucleotides as pharmacological tools and as therapeutic agents. With properly designed and executed experiments, it has been possible to demonstrate selective inhibition of gene expression, owing to an antisense mechanisms of action both in cell culture-based ...
Stanley T. Crooke, C F Bennett
openaire   +3 more sources

Specificity of antisense oligonucleotides

Perspectives in Drug Discovery and Design, 1996
Antisense oligodeoxynucleotides that are sufficiently long to specify unique species of mRNA may direct ribonuclease H (RNase H) to cleave nontargeted mRNAs at sites of partial complementarity, both in cell-free systems and in living cells. Specificity of antisense action against selected gene expression may be achieved by increasing the stringency of ...
openaire   +2 more sources